Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, discusses the impact of next-generation BTK inhibitors (BTKis) on the treatment landscape of chronic lymphocytic leukemia (CLL). Dr Al-Sawaf highlights the ALPINE and ELEVATE-RR trials (NCT03734016; NCT02477696) and the lower risk of cardiovascular toxicities seen with these agents. Dr Al-Sawaf also comments on the exploration of next-generation BTKis as fixed-duration treatments. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть